STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE...

HemaSphere 2019 / 06 Vol. 3

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

Hulin, C., Moreau, P., Attal, M., Belhadj, K., Benboubker, L., Caillot, D., Facon, T., Garderet, L., Kuhnowski, F., Stoppa, A.-M., Kolb, B., Tiab, M., Sonneveld, P., Jie, K.-S., Westerman, M., Pei, L.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
3
Journal:
HemaSphere
DOI:
10.1097/01.HS9.0000560680.23378.f5
Date:
June, 2019
File:
PDF, 183 KB
2019
Conversion to is in progress
Conversion to is failed